Depomed, a US-based pharmaceutical firm, has launched Lazanda (fentanyl) nasal spray along with a new, dedicated team of regional sales specialists and the signature support program for patients with breakthrough cancer pain. Lazanda is ...
Tags: Lazanda Spray, Medicine
Depomed has acquired US and Canadian rights to Archimedes Pharma’s Lazanda (fentanyl) nasal spray for $4m in cash for pain management in cancer patients (BTPc) 18 years of age and older. Leveraging Archimedes patented PecSys drug ...
Tags: Pharma's Lazanda, Medicine
Depomed's lawsuits against Watson Laboratories and Par Pharmaceutical in relation to Abbreviated New Drug Applications (ANDAs) for Gralise (gabapentin) have been dismissed. The company said that both the companies no longer sought ...
Tags: Depomed, Watson Laboratories, Par Pharmaceutical, lawsuit
Depomed has attained Zipsor (diclofenac potassium) Liquid Filled Capsule rights from Xanodyne Pharmaceuticals for $25.9m of cash. Depomed acquired the product in return for potential milestone payments based on the sales of Zipsor and ...
Tags: Zipsor Liquid Filled Capsule, Pharmaceuticals, moderate acute pain
Janssen Pharmaceuticals has signed a licensing deal with Depomed for its Acuform gastric retentive drug delivery technology. As per the agreement, Janssen gained non-exclusive license and other rights to certain Acuform patents and in ...
Tags: Janssen Pharmaceuticals, Acuform Patents, drug delivery technology